Enliven Therapeutics Files Definitive Proxy Statement
Ticker: ELVN · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1672619
| Field | Detail |
|---|---|
| Company | Enliven Therapeutics, Inc. (ELVN) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, corporate-governance
TL;DR
Enliven Therapeutics (formerly IMARA) filed its proxy statement for the June 24th shareholder meeting. Standard stuff.
AI Summary
Enliven Therapeutics, Inc. (formerly IMARA Inc.) filed its definitive proxy statement (DEF 14A) on April 28, 2025, for its annual meeting on June 24, 2025. The company, incorporated in Delaware and based in Boulder, CO, operates in the pharmaceutical preparations sector. This filing is a standard procedural document for soliciting shareholder votes.
Why It Matters
This filing provides shareholders with essential information regarding the upcoming annual meeting, including details on director nominations and other matters to be voted upon, allowing them to make informed decisions.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing, which is a standard disclosure document for public companies and does not inherently present new risks.
Key Numbers
- 20250428 — Filing Date (Date the DEF 14A was filed with the SEC.)
- 20250624 — Meeting Date (Date of the shareholder meeting for which the proxy statement is issued.)
Key Players & Entities
- Enliven Therapeutics, Inc. (company) — Registrant
- IMARA Inc. (company) — Former company name
- 20250428 (date) — Filing date
- 20250624 (date) — Meeting date
- 0001672619 (company) — Central Index Key
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by a company to solicit proxies from its shareholders for an upcoming shareholder meeting, providing details on matters to be voted upon.
When was this specific DEF 14A filed?
This DEF 14A filing for Enliven Therapeutics, Inc. was filed on April 28, 2025.
What is the former name of Enliven Therapeutics, Inc.?
The former name of Enliven Therapeutics, Inc. was IMARA Inc., with a date of name change on April 19, 2016.
Where is Enliven Therapeutics, Inc. headquartered?
Enliven Therapeutics, Inc. is headquartered in Boulder, Colorado, with its business and mail address listed as 6200 Lookout Road, Boulder, CO 80301.
What is the fiscal year end for Enliven Therapeutics, Inc.?
The fiscal year end for Enliven Therapeutics, Inc. is December 31 (1231).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Enliven Therapeutics, Inc. (ELVN).